ExoDxProstate Testing

The Department of Veterans Affairs Veterans Integrated Service Network 7 has published a Special Notice of Intent to Sole Source an acquisition for ExoDx Prostate Testing services. The notice, posted December 29, 2025, announces the VA's intent to procure diagnostic testing services directly from Exosome Diagnostics, Inc. without competitive bidding. The contracting activity is being conducted for the Charlie Norwood VA Medical Center (CNVAMC) located in Augusta, Georgia. The procurement falls under NAICS code 621511 (Medical Laboratories) and PSC code 6515 (Medical and Surgical Instruments, Equipment, and Supplies). This is not a set-aside acquisition, meaning it is available to all contractor types. The notice is classified as a Special Notice opportunity with a response deadline of December 31, 2025.

The VA intends to sole source this contract to Exosome Diagnostics, Inc., designating the company as the sole authorized provider for ExoDx Prostate (IntelliScore) testing. Exosome Diagnostics will be responsible for receiving urine specimens from CNVAMC, performing the ExoDx Prostate Test on all medical specimens, and returning final results via fax to the facility laboratory. The contractor must provide all materials, equipment, supervision, and staffing required to execute the full scope of services and must notify CNVAMC laboratory personnel of any significantly delayed results due to technical or instrumentation issues. While the government has indicated its intent to sole source to Exosome Diagnostics, other interested businesses may express their capability to provide these services by contacting contracting officer Steven Timmons; however, the government retains sole discretion to determine whether to open the requirement to competitive bidding. Interested parties should note that no formal solicitation document is currently available.